Experience

Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Brain tumours

  • Health Economics and Translational Advisory Board on paediatric brain tumours
  • Support in personalised medicine health economics on brain tumours

Breast cancer

  • Global value dossier for treatment in breast cancer
  • Data collection of costs associated with breast cancer care
  • Manuscript on the German model for a hormonal drug used in the treatment of breast cancer
  • Development of two budget impact models in breast cancer with population data by city
  • Two budget impact models for Italy for an injectable chemotherapy drug for breast cancer
  • Budget impact model in breast cancer for France
  • Development of a cost-calculator for a biosimilar for breast cancer
  • Payer value deck in breast cancer
  • Payer value deck update for a breast cancer biosimilar
  • Burden of disease deck in breast cancer
  • Response to payer questions in breast cancer
  • Response to payer questions update for a breast cancer biosimilar
  • Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
  • One-pager communication in a breast cancer biosimilar
  • Productivity and QoL study in breast cancer
  • Literature review and consultancy on breast cancer
  • e-v@luate platforms in breast cancer

HER2 positive breast cancer

  • Literature review of productivity data in HER2 positive breast cancer
  • Budget impact model for a biosimilar in HER2 breast cancer

Advanced breast cancer

  • Development of a perceived tolerability questionnaire in first line treatment of advanced breast cancer
  • Strategy for an injectable chemotherapy drug for advanced breast cancer and submission to NICE/SMC
  • Budget impact model and analysis for an injectable chemotherapy drug for advanced breast cancer in 5 EU countries
  • Economic evaluation of a therapy for postmenopausal women with advanced breast cancer (with the perspective of 3rd party national and local payers in the UK)
  • Development and population of an economic model in advanced breast cancer
  • Conference poster on a cost utility analysis of two treatments for advanced breast cancer
  • Conference poster on the economic evaluation of a therapy for postmenopausal women with advanced breast cancer
  • Phase IV non-interventional prospective observational study comparing patient reported outcomes in advanced breast cancer
  • PRO label review manuscript development in advanced/metastatic breast cancer

Metastatic breast cancer

  • Value dossier and e-v@luate platform in metastatic breast cancer
  • Scientific communication of cost-effectiveness analysis in metastatic breast cancer
  • PRO knowledge base instruments and methods library for metastatic breast cancer

Triple negative breast cancer

  • Global value dossier and upload to e-v@luate platform in triple negative breast cancer
  • Data analyses on a multi-indication budget impact model and cost utility model in triple negative breast cancer
  • Standalone budget impact models in triple negative breast cancer

Bronchitis

  • Development of a cough and sputum questionnaire in chronic bronchitis in 7 languages
  • Validation of a cough and sputum questionnaire in chronic bronchitis
  • Development and validation of a patient diary for evaluating acute exacerbation of chronic bronchitis
  • Conducting European focus group sessions for acute exacerbation of chronic bronchitis
  • Validation of a patient diary for evaluating acute exacerbation of chronic bronchitis (AECB)

Cancer-related pain, fatigue and side effects

Cancer-related pain and fatigue

  • Initial consultation to design a study in order to generate health utilities values associated with different levels of cancer-related pain
  • Utility study in breakthrough cancer pain
  • Update of report for utility elicitation in breakthrough cancer pain
  • Abstract, manuscript and budget impact model on breakthrough cancer pain
  • Training in pilot budget impact model for a treatment for patients with breakthrough cancer pain
  • SMC submission in breakthrough cancer pain
  • Development of a breakthrough cancer pain submission to the All Wales Medicines Strategy Group (AWMSG)
  • Attendance at an AWMSG meeting with regards to strategic consultancy in breakthrough cancer pain
  • Expert interviews and amendment project to heath economic model for a treatment for breakthrough cancer pain
  • Economic evaluation of a treatment for breakthrough cancer pain in Canada
  • Budget impact tool for a treatment for patients with breakthrough cancer pain in the UK
  • Consulting support and development of a briefing document to support fatigue symptom claims in cancer pain
  • Recommendation of a measure of chronic cancer pain
  • Assessment of a pain communication tool for advanced cancer patients: a cross-sectional survey
  • Qualitative research for the Cancer-Related Fatigue Consortium
  • Phase II cognitive interviews on Patient-Reported Outcomes of Fatigue – Cancer (PROOF-C)
  • Cancer-related fatigue consortium: qualitative research in the experience of fatigue among cancer patients
  • Qualitative research on the experience of fatigue among cancer patients
  • PRO development, abstracts and posters on cancer-related fatigue

Cancer-related anaemia

  • Linking a cost utility assessment model with a budget impact model for treatment for anaemia in cancer
  • NICE consultancy for a treatment for chemotherapy-induced anaemia
  • Statistical pharmacoeconomic analysis of patient level data for a treatment for anaemia following chemotherapy
  • Phase II cognitive interviews and regulatory support in inflammatory anaemia in cancer
  • Evaluation of the PRO landscape using a systematic literature review on chemo-induced anaemia in oncology

Other cancer-related side effects

  • Value dossier on a drug used to treat febrile neutropenia
  • Plan, execute and follow up a Train-the-Trainer meeting on chemotherapy-induced febrile neutropenia
  • Development of a PRO measure in muscle wasting (cancer cachexia) in prostate cancer, sarcopenia, gastric cancer and colorectal cancer
  • Debriefing of the cancer associated fibroblasts (CaF) PRO
  • SMC re-submission and economic analysis for a treatment for anthracycline extravasation
  • Case control study of costs associated with a treatment for oral mucositis in transplant patients
  • Literature review and recommendations on PROs for peripheral neuropathy due to chemotherapy in cancer patients
  • Review of PRO instruments for use in uveal melanoma and biliary tract cancer

Cataracts

  • Etiology and meta-analysis of posterior cacular opacification comparing two lens types
  • Meta-analysis of phacoemulsification, extracapsular cataract extraction (ECCE) and manual small incision cataract surgery (MSICS) in Asia
  • Formal recommendations on a regulatory briefing document for intraocular cataract lenses
  • Development of a PRO questionnaire to assess implantation of an intraocular lens in cataract patients
  • Cognitive interviews for the development of a PRO to assess intraocular lenses in cataract patients
  • Support on the intraocular lenses Expert Focus Group
  • Quality of life study in cataracts

Cervical cancer

  • Development of a PRO strategy in cervical cancer and HPV
  • Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

Cervical dystonia

  • Validation and reliability of the Pictorial Spasmodic Torticollis Rating Scale (P-STRS) in cervical dystonia
  • Development of a screening tool in cervical dystonia (Delphi panel) and validate using registry
  • Validation of a screening tool in cervical dystonia
  • Measurement strategy in cervical dystonia
  • Content validity of global questionnaires in cervical dystonia

Chronic obstructive pulmonary disease (COPD)

  • Value proposition for a new metered dose inhaler to treat chronic obstructive pulmonary disease (COPD)
  • External expert assessment of a drug for COPD
  • Development of a global market access value pack to support regional/local access teams and HTA submissions in COPD
  • Value pack (objection handler and budget impact/cost minimisation model) in COPD
  • Conference abstract and poster development on COPD
  • Manuscript on the budget impact of a new treatment in COPD
  • Updates to critical handling error manuscript in chronic obstructive pulmonary disease (COPD)
  • Structured literature review and qualitative interviews with payers/HCPs on a device for COPD
  • Protocol development support for a conjoint patient preference study in COPD
  • PRO strategy support for an inhaler treatment for COPD
  • Literature review, FDA briefing document and FDA meeting related to the development of an ePRO for well controlled days in COPD
  • Targeted literature review of PRO measures in frequently exacerbating COPD patients
  • Literature review and research around treatment experiences of patients with COPD
  • Exit interviews to explore patient disease burden, treatment satisfaction and clinical trial participation in muscle wasting associated with COPD
  • Development and delivery of a manuscript on the results from a trial in COPD
  • Translation and validation of the chronic obstructive pulmonary disease population screener (COPD-PS) in Japan
  • Poster presentation on the validation of the COPD-PS in Japan
  • Manuscript on the validation of the COPD-PS in Japan
  • Poster on the development of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD
  • Development of a user manual for the cough and sputum assessment questionnaire
  • Validation of the CASA-Q trial
  • Cross-team review of a CASA-Q PRO dossier in COPD for submission to the FDA
  • FDA support for the CASA-Q in COPD
  • Support at investigator meetings for the CASA-Q
  • Psychometric validation of the Shortness of Breath Questionnaire in COPD
  • Validation of a questionnaire for assessing control status of patients with COPD
  • Development of a dyspnoea scale in COPD
  • Development and validation of a satisfaction questionnaire in COPD
  • Development of a symptom diary in COPD
  • Validation of a patient diary to assess symptoms of COPD
  • Development of a poster and validation of a questionnaire in COPD
  • Development and validation of an ePRO in COPD
  • Mixed treatment comparison between competing interventions for COPD
  • Association between exacerbations, a respiratory questionnaire and the use of rescue medication in COPD
  • Network meta-analysis of two treatments for COPD
  • Network meta-analysis of one drug versus fixed dose combinations in COPD
  • Network meta-analysis of competing interventions in the management of COPD
  • Conference presentation on a network meta-analysis of a treatment for COPD
  • Development of a preference-based instrument specific to COPD
  • Validation of a patient diary for evaluating acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

Clostridium difficile

  • Pre-budget impact analysis and economic advice for personalized medicine: approaches to diagnose and control clostridium difficile infections